Neflamapimod
Neflamapimod is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Clinical Trials (7)
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7